Regulatory approval

Published by the European Medicines Agency. Approved

The European Medicines Agency (EMA) has authorized Blincyto (blinatumomab) as a monotherapy treatment option as part of consolidation therapy for the treatment of adult patients with newly diagnosed Philidelphia chromosome negative CD19 positive B-cell precursor acute lymphoblastic leukaemia (ALL).

This is written in the approval document as:

BLINCYTO is indicated as monotherapy as part of consolidation therapy for the treatment of adult patients with newly diagnosed Philadelphia chromosome negative CD19 positive B-cell precusor acute lymphoblastic leukaemia (ALL).

Citation

Amgen Europe B.V. Blincyto (blinatumomab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/blincyto-epar-product-information_en.pdf. Revised July 2025. Accessed August 29, 2025.

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
EMA (1)	CD19 +, not BCR::ABL1	Acute Lymphoblastic Leukemia	Blinatumomab

Contributions

Date	Contributor	Description
2025-08-29	Van Allen lab	On 2025-02-10, the EMA published an EPAR - Assessment report - Variation that provided a new indication for Blincyto (blinatumomab).
2025-01-23	European Medicines Agency	Indication received approval from the European Commission.